Alnylam Pharmaceuticals Inc Asset Resilience Ratio
Alnylam Pharmaceuticals Inc asset resilience ratio. Alnylam Pharmaceuticals Inc (ALNY) has an Asset Resilience Ratio of 25.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Alnylam Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alnylam Pharmaceuticals Inc (2002–2025)
Asset resilience ratio of Alnylam Pharmaceuticals Inc from 2002 to 2025. This chart shows how Alnylam Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ALNY cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Alnylam Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALNY total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.25 Billion | 25.19% |
| Total Liquid Assets | $1.25 Billion | 25.19% |
Asset Resilience Insights
- Very High Liquidity: Alnylam Pharmaceuticals Inc maintains exceptional liquid asset reserves at 25.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alnylam Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Alnylam Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Alnylam Pharmaceuticals Inc Asset Resilience Ratio by Year (2002–2025)
Alnylam Pharmaceuticals Inc asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Alnylam Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.19% | $1.25 Billion | $4.97 Billion | -15.56pp |
| 2024-12-31 | 40.76% | $1.73 Billion | $4.24 Billion | -1.72pp |
| 2023-12-31 | 42.47% | $1.63 Billion | $3.83 Billion | +5.08pp |
| 2022-12-31 | 37.39% | $1.33 Billion | $3.55 Billion | -6.95pp |
| 2021-12-31 | 44.34% | $1.62 Billion | $3.64 Billion | +3.90pp |
| 2020-12-31 | 40.44% | $1.38 Billion | $3.41 Billion | -0.85pp |
| 2019-12-31 | 41.29% | $988.98 Million | $2.40 Billion | -0.87pp |
| 2018-12-31 | 42.16% | $664.01 Million | $1.57 Billion | -10.24pp |
| 2017-12-31 | 52.40% | $1.05 Billion | $1.99 Billion | +18.10pp |
| 2016-12-31 | 34.30% | $433.18 Million | $1.26 Billion | -30.58pp |
| 2015-12-31 | 64.88% | $899.64 Million | $1.39 Billion | +7.32pp |
| 2014-12-31 | 57.57% | $621.51 Million | $1.08 Billion | +11.75pp |
| 2013-12-31 | 45.82% | $192.70 Million | $420.53 Million | +20.99pp |
| 2012-12-31 | 24.84% | $71.41 Million | $287.52 Million | -2.18pp |
| 2011-12-31 | 27.02% | $76.17 Million | $281.92 Million | -13.29pp |
| 2010-12-31 | 40.31% | $158.53 Million | $393.26 Million | +10.41pp |
| 2009-12-31 | 29.90% | $143.93 Million | $481.38 Million | -13.12pp |
| 2008-12-31 | 43.02% | $238.60 Million | $554.68 Million | -14.66pp |
| 2007-12-31 | 57.67% | $284.79 Million | $493.79 Million | +20.46pp |
| 2006-12-31 | 37.21% | $89.31 Million | $240.01 Million | -28.11pp |
| 2005-12-31 | 65.32% | $64.25 Million | $98.35 Million | +26.34pp |
| 2004-12-31 | 38.99% | $25.77 Million | $66.11 Million | +37.93pp |
| 2003-12-31 | 1.06% | $373.00K | $35.18 Million | +0.94pp |
| 2002-12-31 | 0.12% | $19.00K | $16.11 Million | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more